Why the study?
Cerebral vasospasm following subarachnoid hemorrhage is a critical complication driven by imbalances between vasodilators and vasoconstrictors, warranting exploration of the bidirectional interplay between nitric oxide and endothelin-1 in its pathogenesis and therapeutic targeting.
Answers are grounded in this paper and cite their sources.
This review summarizes the pathophysiological interplay between nitric oxide and endothelin-1 in cerebral vasospasm after subarachnoid hemorrhage and highlights potential targeted therapies.
Cerebral vasospasm (CVS) following a subarachnoid hemorrhage (SAH) is a critical complication driven by imbalances between vasodilators and vasoconstrictors. This review explores the bidirectional interplay between nitric oxide (NO) and endothelin-1 (ET-1) in CVS pathogenesis. NO, a potent vasodilator mainly produced by endothelial and neuronal nitric oxide synthase (eNOS/nNOS) under normal physiological conditions, is scavenged early after SAH by hemoglobin derivatives, leading to microcirculatory dysfunction, pericyte constriction, and impaired neurovascular coupling. Conversely, ET-1 exacerbates vasoconstriction by suppressing NO synthesis via ROS-dependent eNOS uncoupling and Rho-kinase activation. The NO/ET-1 axis further influences delayed cerebral ischemia (DCI) through mechanisms like 20-HETE-mediated cGMP suppression and oxidative stress. Emerging therapies—including NO donors, NOS gene therapy, and ET-1 receptor antagonists—aim to restore this balance. Understanding these pathways offers translational potential for mitigating CVS and improving outcomes post-SAH.
No takes yet. Share an insight, caveat, or question.
Becker et al. (2025) conducted a review in Cerebral vasospasm and delayed cerebral ischemia following subarachnoid hemorrhage. Pharmacotherapies targeting the NO/ET-1 axis (NO donors, ET-1 receptor antagonists, 20-HETE inhibitors) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: